INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30901, 19875, 'Venlafaxine', 'Kidney Diseases', 'The clearance of SNRI antidepressants is decreased in subjects with renal impairment.  SNRIs should be used with caution in this group of patients and a dose adjustment is recommended in those with moderate and severe renal impairment.  The use of SNRIs is not recommended in patients with end-stage renal disease.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30902, 20709, 'Venlafaxine', 'Kidney Diseases', 'The clearance of SNRI antidepressants is decreased in subjects with renal impairment.  SNRIs should be used with caution in this group of patients and a dose adjustment is recommended in those with moderate and severe renal impairment.  The use of SNRIs is not recommended in patients with end-stage renal disease.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30903, 20711, 'Venlafaxine', 'Kidney Diseases', 'The clearance of SNRI antidepressants is decreased in subjects with renal impairment.  SNRIs should be used with caution in this group of patients and a dose adjustment is recommended in those with moderate and severe renal impairment.  The use of SNRIs is not recommended in patients with end-stage renal disease.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30904, 20712, 'Venlafaxine', 'Kidney Diseases', 'The clearance of SNRI antidepressants is decreased in subjects with renal impairment.  SNRIs should be used with caution in this group of patients and a dose adjustment is recommended in those with moderate and severe renal impairment.  The use of SNRIs is not recommended in patients with end-stage renal disease.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30905, 21072, 'Venlafaxine', 'Kidney Diseases', 'The clearance of SNRI antidepressants is decreased in subjects with renal impairment.  SNRIs should be used with caution in this group of patients and a dose adjustment is recommended in those with moderate and severe renal impairment.  The use of SNRIs is not recommended in patients with end-stage renal disease.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30906, 29096, 'Venlafaxine', 'Kidney Diseases', 'The clearance of SNRI antidepressants is decreased in subjects with renal impairment.  SNRIs should be used with caution in this group of patients and a dose adjustment is recommended in those with moderate and severe renal impairment.  The use of SNRIs is not recommended in patients with end-stage renal disease.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30907, 29097, 'Venlafaxine', 'Kidney Diseases', 'The clearance of SNRI antidepressants is decreased in subjects with renal impairment.  SNRIs should be used with caution in this group of patients and a dose adjustment is recommended in those with moderate and severe renal impairment.  The use of SNRIs is not recommended in patients with end-stage renal disease.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30908, 29098, 'Venlafaxine', 'Kidney Diseases', 'The clearance of SNRI antidepressants is decreased in subjects with renal impairment.  SNRIs should be used with caution in this group of patients and a dose adjustment is recommended in those with moderate and severe renal impairment.  The use of SNRIs is not recommended in patients with end-stage renal disease.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30909, 29099, 'Venlafaxine', 'Kidney Diseases', 'The clearance of SNRI antidepressants is decreased in subjects with renal impairment.  SNRIs should be used with caution in this group of patients and a dose adjustment is recommended in those with moderate and severe renal impairment.  The use of SNRIs is not recommended in patients with end-stage renal disease.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30910, 29103, 'Venlafaxine', 'Kidney Diseases', 'The clearance of SNRI antidepressants is decreased in subjects with renal impairment.  SNRIs should be used with caution in this group of patients and a dose adjustment is recommended in those with moderate and severe renal impairment.  The use of SNRIs is not recommended in patients with end-stage renal disease.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30911, 29110, 'Venlafaxine', 'Kidney Diseases', 'The clearance of SNRI antidepressants is decreased in subjects with renal impairment.  SNRIs should be used with caution in this group of patients and a dose adjustment is recommended in those with moderate and severe renal impairment.  The use of SNRIs is not recommended in patients with end-stage renal disease.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30912, 29111, 'Venlafaxine', 'Kidney Diseases', 'The clearance of SNRI antidepressants is decreased in subjects with renal impairment.  SNRIs should be used with caution in this group of patients and a dose adjustment is recommended in those with moderate and severe renal impairment.  The use of SNRIs is not recommended in patients with end-stage renal disease.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30913, 29212, 'Venlafaxine', 'Kidney Diseases', 'The clearance of SNRI antidepressants is decreased in subjects with renal impairment.  SNRIs should be used with caution in this group of patients and a dose adjustment is recommended in those with moderate and severe renal impairment.  The use of SNRIs is not recommended in patients with end-stage renal disease.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30914, 29213, 'Venlafaxine', 'Kidney Diseases', 'The clearance of SNRI antidepressants is decreased in subjects with renal impairment.  SNRIs should be used with caution in this group of patients and a dose adjustment is recommended in those with moderate and severe renal impairment.  The use of SNRIs is not recommended in patients with end-stage renal disease.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30915, 29214, 'Venlafaxine', 'Kidney Diseases', 'The clearance of SNRI antidepressants is decreased in subjects with renal impairment.  SNRIs should be used with caution in this group of patients and a dose adjustment is recommended in those with moderate and severe renal impairment.  The use of SNRIs is not recommended in patients with end-stage renal disease.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30916, 30447, 'Venlafaxine', 'Kidney Diseases', 'The clearance of SNRI antidepressants is decreased in subjects with renal impairment.  SNRIs should be used with caution in this group of patients and a dose adjustment is recommended in those with moderate and severe renal impairment.  The use of SNRIs is not recommended in patients with end-stage renal disease.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30917, 31559, 'Venlafaxine', 'Kidney Diseases', 'The clearance of SNRI antidepressants is decreased in subjects with renal impairment.  SNRIs should be used with caution in this group of patients and a dose adjustment is recommended in those with moderate and severe renal impairment.  The use of SNRIs is not recommended in patients with end-stage renal disease.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30918, 32779, 'Venlafaxine', 'Kidney Diseases', 'The clearance of SNRI antidepressants is decreased in subjects with renal impairment.  SNRIs should be used with caution in this group of patients and a dose adjustment is recommended in those with moderate and severe renal impairment.  The use of SNRIs is not recommended in patients with end-stage renal disease.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30919, 4005, 'Venlafaxine', 'Liver Diseases', 'Venlafaxine is metabolized by the liver, and both the parent drug and metabolites are excreted by the kidney.  Patients with renal and/or liver disease may be at greater risk for adverse effects from venlafaxine due to decreased drug clearance.  Therapy with venlafaxine should be administered cautiously in patients with impaired renal and/or hepatic function.  A reduction in the total daily dosage is recommended.  The manufacturer suggests a 50% reduction in patients with moderate hepatic impairment (possibly more in patients with cirrhosis), a 25% reduction in patients with mild to moderate renal impairment, and a 50% reduction in patients undergoing hemodialysis (to be administered after dialysis treatment).', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30920, 4006, 'Venlafaxine', 'Liver Diseases', 'Venlafaxine is metabolized by the liver, and both the parent drug and metabolites are excreted by the kidney.  Patients with renal and/or liver disease may be at greater risk for adverse effects from venlafaxine due to decreased drug clearance.  Therapy with venlafaxine should be administered cautiously in patients with impaired renal and/or hepatic function.  A reduction in the total daily dosage is recommended.  The manufacturer suggests a 50% reduction in patients with moderate hepatic impairment (possibly more in patients with cirrhosis), a 25% reduction in patients with mild to moderate renal impairment, and a 50% reduction in patients undergoing hemodialysis (to be administered after dialysis treatment).', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30921, 4010, 'Venlafaxine', 'Liver Diseases', 'Venlafaxine is metabolized by the liver, and both the parent drug and metabolites are excreted by the kidney.  Patients with renal and/or liver disease may be at greater risk for adverse effects from venlafaxine due to decreased drug clearance.  Therapy with venlafaxine should be administered cautiously in patients with impaired renal and/or hepatic function.  A reduction in the total daily dosage is recommended.  The manufacturer suggests a 50% reduction in patients with moderate hepatic impairment (possibly more in patients with cirrhosis), a 25% reduction in patients with mild to moderate renal impairment, and a 50% reduction in patients undergoing hemodialysis (to be administered after dialysis treatment).', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30922, 6386, 'Venlafaxine', 'Liver Diseases', 'Venlafaxine is metabolized by the liver, and both the parent drug and metabolites are excreted by the kidney.  Patients with renal and/or liver disease may be at greater risk for adverse effects from venlafaxine due to decreased drug clearance.  Therapy with venlafaxine should be administered cautiously in patients with impaired renal and/or hepatic function.  A reduction in the total daily dosage is recommended.  The manufacturer suggests a 50% reduction in patients with moderate hepatic impairment (possibly more in patients with cirrhosis), a 25% reduction in patients with mild to moderate renal impairment, and a 50% reduction in patients undergoing hemodialysis (to be administered after dialysis treatment).', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30923, 12174, 'Venlafaxine', 'Liver Diseases', 'Venlafaxine is metabolized by the liver, and both the parent drug and metabolites are excreted by the kidney.  Patients with renal and/or liver disease may be at greater risk for adverse effects from venlafaxine due to decreased drug clearance.  Therapy with venlafaxine should be administered cautiously in patients with impaired renal and/or hepatic function.  A reduction in the total daily dosage is recommended.  The manufacturer suggests a 50% reduction in patients with moderate hepatic impairment (possibly more in patients with cirrhosis), a 25% reduction in patients with mild to moderate renal impairment, and a 50% reduction in patients undergoing hemodialysis (to be administered after dialysis treatment).', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30924, 17234, 'Venlafaxine', 'Liver Diseases', 'Venlafaxine is metabolized by the liver, and both the parent drug and metabolites are excreted by the kidney.  Patients with renal and/or liver disease may be at greater risk for adverse effects from venlafaxine due to decreased drug clearance.  Therapy with venlafaxine should be administered cautiously in patients with impaired renal and/or hepatic function.  A reduction in the total daily dosage is recommended.  The manufacturer suggests a 50% reduction in patients with moderate hepatic impairment (possibly more in patients with cirrhosis), a 25% reduction in patients with mild to moderate renal impairment, and a 50% reduction in patients undergoing hemodialysis (to be administered after dialysis treatment).', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30925, 17235, 'Venlafaxine', 'Liver Diseases', 'Venlafaxine is metabolized by the liver, and both the parent drug and metabolites are excreted by the kidney.  Patients with renal and/or liver disease may be at greater risk for adverse effects from venlafaxine due to decreased drug clearance.  Therapy with venlafaxine should be administered cautiously in patients with impaired renal and/or hepatic function.  A reduction in the total daily dosage is recommended.  The manufacturer suggests a 50% reduction in patients with moderate hepatic impairment (possibly more in patients with cirrhosis), a 25% reduction in patients with mild to moderate renal impairment, and a 50% reduction in patients undergoing hemodialysis (to be administered after dialysis treatment).', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30926, 17236, 'Venlafaxine', 'Liver Diseases', 'Venlafaxine is metabolized by the liver, and both the parent drug and metabolites are excreted by the kidney.  Patients with renal and/or liver disease may be at greater risk for adverse effects from venlafaxine due to decreased drug clearance.  Therapy with venlafaxine should be administered cautiously in patients with impaired renal and/or hepatic function.  A reduction in the total daily dosage is recommended.  The manufacturer suggests a 50% reduction in patients with moderate hepatic impairment (possibly more in patients with cirrhosis), a 25% reduction in patients with mild to moderate renal impairment, and a 50% reduction in patients undergoing hemodialysis (to be administered after dialysis treatment).', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30927, 18100, 'Venlafaxine', 'Liver Diseases', 'Venlafaxine is metabolized by the liver, and both the parent drug and metabolites are excreted by the kidney.  Patients with renal and/or liver disease may be at greater risk for adverse effects from venlafaxine due to decreased drug clearance.  Therapy with venlafaxine should be administered cautiously in patients with impaired renal and/or hepatic function.  A reduction in the total daily dosage is recommended.  The manufacturer suggests a 50% reduction in patients with moderate hepatic impairment (possibly more in patients with cirrhosis), a 25% reduction in patients with mild to moderate renal impairment, and a 50% reduction in patients undergoing hemodialysis (to be administered after dialysis treatment).', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30928, 18106, 'Venlafaxine', 'Liver Diseases', 'Venlafaxine is metabolized by the liver, and both the parent drug and metabolites are excreted by the kidney.  Patients with renal and/or liver disease may be at greater risk for adverse effects from venlafaxine due to decreased drug clearance.  Therapy with venlafaxine should be administered cautiously in patients with impaired renal and/or hepatic function.  A reduction in the total daily dosage is recommended.  The manufacturer suggests a 50% reduction in patients with moderate hepatic impairment (possibly more in patients with cirrhosis), a 25% reduction in patients with mild to moderate renal impairment, and a 50% reduction in patients undergoing hemodialysis (to be administered after dialysis treatment).', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30929, 19873, 'Venlafaxine', 'Liver Diseases', 'Venlafaxine is metabolized by the liver, and both the parent drug and metabolites are excreted by the kidney.  Patients with renal and/or liver disease may be at greater risk for adverse effects from venlafaxine due to decreased drug clearance.  Therapy with venlafaxine should be administered cautiously in patients with impaired renal and/or hepatic function.  A reduction in the total daily dosage is recommended.  The manufacturer suggests a 50% reduction in patients with moderate hepatic impairment (possibly more in patients with cirrhosis), a 25% reduction in patients with mild to moderate renal impairment, and a 50% reduction in patients undergoing hemodialysis (to be administered after dialysis treatment).', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30930, 19874, 'Venlafaxine', 'Liver Diseases', 'Venlafaxine is metabolized by the liver, and both the parent drug and metabolites are excreted by the kidney.  Patients with renal and/or liver disease may be at greater risk for adverse effects from venlafaxine due to decreased drug clearance.  Therapy with venlafaxine should be administered cautiously in patients with impaired renal and/or hepatic function.  A reduction in the total daily dosage is recommended.  The manufacturer suggests a 50% reduction in patients with moderate hepatic impairment (possibly more in patients with cirrhosis), a 25% reduction in patients with mild to moderate renal impairment, and a 50% reduction in patients undergoing hemodialysis (to be administered after dialysis treatment).', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30931, 19875, 'Venlafaxine', 'Liver Diseases', 'Venlafaxine is metabolized by the liver, and both the parent drug and metabolites are excreted by the kidney.  Patients with renal and/or liver disease may be at greater risk for adverse effects from venlafaxine due to decreased drug clearance.  Therapy with venlafaxine should be administered cautiously in patients with impaired renal and/or hepatic function.  A reduction in the total daily dosage is recommended.  The manufacturer suggests a 50% reduction in patients with moderate hepatic impairment (possibly more in patients with cirrhosis), a 25% reduction in patients with mild to moderate renal impairment, and a 50% reduction in patients undergoing hemodialysis (to be administered after dialysis treatment).', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30932, 20709, 'Venlafaxine', 'Liver Diseases', 'Venlafaxine is metabolized by the liver, and both the parent drug and metabolites are excreted by the kidney.  Patients with renal and/or liver disease may be at greater risk for adverse effects from venlafaxine due to decreased drug clearance.  Therapy with venlafaxine should be administered cautiously in patients with impaired renal and/or hepatic function.  A reduction in the total daily dosage is recommended.  The manufacturer suggests a 50% reduction in patients with moderate hepatic impairment (possibly more in patients with cirrhosis), a 25% reduction in patients with mild to moderate renal impairment, and a 50% reduction in patients undergoing hemodialysis (to be administered after dialysis treatment).', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30933, 20711, 'Venlafaxine', 'Liver Diseases', 'Venlafaxine is metabolized by the liver, and both the parent drug and metabolites are excreted by the kidney.  Patients with renal and/or liver disease may be at greater risk for adverse effects from venlafaxine due to decreased drug clearance.  Therapy with venlafaxine should be administered cautiously in patients with impaired renal and/or hepatic function.  A reduction in the total daily dosage is recommended.  The manufacturer suggests a 50% reduction in patients with moderate hepatic impairment (possibly more in patients with cirrhosis), a 25% reduction in patients with mild to moderate renal impairment, and a 50% reduction in patients undergoing hemodialysis (to be administered after dialysis treatment).', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30934, 20712, 'Venlafaxine', 'Liver Diseases', 'Venlafaxine is metabolized by the liver, and both the parent drug and metabolites are excreted by the kidney.  Patients with renal and/or liver disease may be at greater risk for adverse effects from venlafaxine due to decreased drug clearance.  Therapy with venlafaxine should be administered cautiously in patients with impaired renal and/or hepatic function.  A reduction in the total daily dosage is recommended.  The manufacturer suggests a 50% reduction in patients with moderate hepatic impairment (possibly more in patients with cirrhosis), a 25% reduction in patients with mild to moderate renal impairment, and a 50% reduction in patients undergoing hemodialysis (to be administered after dialysis treatment).', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30935, 21072, 'Venlafaxine', 'Liver Diseases', 'Venlafaxine is metabolized by the liver, and both the parent drug and metabolites are excreted by the kidney.  Patients with renal and/or liver disease may be at greater risk for adverse effects from venlafaxine due to decreased drug clearance.  Therapy with venlafaxine should be administered cautiously in patients with impaired renal and/or hepatic function.  A reduction in the total daily dosage is recommended.  The manufacturer suggests a 50% reduction in patients with moderate hepatic impairment (possibly more in patients with cirrhosis), a 25% reduction in patients with mild to moderate renal impairment, and a 50% reduction in patients undergoing hemodialysis (to be administered after dialysis treatment).', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30936, 29096, 'Venlafaxine', 'Liver Diseases', 'Venlafaxine is metabolized by the liver, and both the parent drug and metabolites are excreted by the kidney.  Patients with renal and/or liver disease may be at greater risk for adverse effects from venlafaxine due to decreased drug clearance.  Therapy with venlafaxine should be administered cautiously in patients with impaired renal and/or hepatic function.  A reduction in the total daily dosage is recommended.  The manufacturer suggests a 50% reduction in patients with moderate hepatic impairment (possibly more in patients with cirrhosis), a 25% reduction in patients with mild to moderate renal impairment, and a 50% reduction in patients undergoing hemodialysis (to be administered after dialysis treatment).', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30937, 29097, 'Venlafaxine', 'Liver Diseases', 'Venlafaxine is metabolized by the liver, and both the parent drug and metabolites are excreted by the kidney.  Patients with renal and/or liver disease may be at greater risk for adverse effects from venlafaxine due to decreased drug clearance.  Therapy with venlafaxine should be administered cautiously in patients with impaired renal and/or hepatic function.  A reduction in the total daily dosage is recommended.  The manufacturer suggests a 50% reduction in patients with moderate hepatic impairment (possibly more in patients with cirrhosis), a 25% reduction in patients with mild to moderate renal impairment, and a 50% reduction in patients undergoing hemodialysis (to be administered after dialysis treatment).', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30938, 29098, 'Venlafaxine', 'Liver Diseases', 'Venlafaxine is metabolized by the liver, and both the parent drug and metabolites are excreted by the kidney.  Patients with renal and/or liver disease may be at greater risk for adverse effects from venlafaxine due to decreased drug clearance.  Therapy with venlafaxine should be administered cautiously in patients with impaired renal and/or hepatic function.  A reduction in the total daily dosage is recommended.  The manufacturer suggests a 50% reduction in patients with moderate hepatic impairment (possibly more in patients with cirrhosis), a 25% reduction in patients with mild to moderate renal impairment, and a 50% reduction in patients undergoing hemodialysis (to be administered after dialysis treatment).', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30939, 29099, 'Venlafaxine', 'Liver Diseases', 'Venlafaxine is metabolized by the liver, and both the parent drug and metabolites are excreted by the kidney.  Patients with renal and/or liver disease may be at greater risk for adverse effects from venlafaxine due to decreased drug clearance.  Therapy with venlafaxine should be administered cautiously in patients with impaired renal and/or hepatic function.  A reduction in the total daily dosage is recommended.  The manufacturer suggests a 50% reduction in patients with moderate hepatic impairment (possibly more in patients with cirrhosis), a 25% reduction in patients with mild to moderate renal impairment, and a 50% reduction in patients undergoing hemodialysis (to be administered after dialysis treatment).', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30940, 29103, 'Venlafaxine', 'Liver Diseases', 'Venlafaxine is metabolized by the liver, and both the parent drug and metabolites are excreted by the kidney.  Patients with renal and/or liver disease may be at greater risk for adverse effects from venlafaxine due to decreased drug clearance.  Therapy with venlafaxine should be administered cautiously in patients with impaired renal and/or hepatic function.  A reduction in the total daily dosage is recommended.  The manufacturer suggests a 50% reduction in patients with moderate hepatic impairment (possibly more in patients with cirrhosis), a 25% reduction in patients with mild to moderate renal impairment, and a 50% reduction in patients undergoing hemodialysis (to be administered after dialysis treatment).', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30941, 29110, 'Venlafaxine', 'Liver Diseases', 'Venlafaxine is metabolized by the liver, and both the parent drug and metabolites are excreted by the kidney.  Patients with renal and/or liver disease may be at greater risk for adverse effects from venlafaxine due to decreased drug clearance.  Therapy with venlafaxine should be administered cautiously in patients with impaired renal and/or hepatic function.  A reduction in the total daily dosage is recommended.  The manufacturer suggests a 50% reduction in patients with moderate hepatic impairment (possibly more in patients with cirrhosis), a 25% reduction in patients with mild to moderate renal impairment, and a 50% reduction in patients undergoing hemodialysis (to be administered after dialysis treatment).', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30942, 29111, 'Venlafaxine', 'Liver Diseases', 'Venlafaxine is metabolized by the liver, and both the parent drug and metabolites are excreted by the kidney.  Patients with renal and/or liver disease may be at greater risk for adverse effects from venlafaxine due to decreased drug clearance.  Therapy with venlafaxine should be administered cautiously in patients with impaired renal and/or hepatic function.  A reduction in the total daily dosage is recommended.  The manufacturer suggests a 50% reduction in patients with moderate hepatic impairment (possibly more in patients with cirrhosis), a 25% reduction in patients with mild to moderate renal impairment, and a 50% reduction in patients undergoing hemodialysis (to be administered after dialysis treatment).', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30943, 29212, 'Venlafaxine', 'Liver Diseases', 'Venlafaxine is metabolized by the liver, and both the parent drug and metabolites are excreted by the kidney.  Patients with renal and/or liver disease may be at greater risk for adverse effects from venlafaxine due to decreased drug clearance.  Therapy with venlafaxine should be administered cautiously in patients with impaired renal and/or hepatic function.  A reduction in the total daily dosage is recommended.  The manufacturer suggests a 50% reduction in patients with moderate hepatic impairment (possibly more in patients with cirrhosis), a 25% reduction in patients with mild to moderate renal impairment, and a 50% reduction in patients undergoing hemodialysis (to be administered after dialysis treatment).', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30944, 29213, 'Venlafaxine', 'Liver Diseases', 'Venlafaxine is metabolized by the liver, and both the parent drug and metabolites are excreted by the kidney.  Patients with renal and/or liver disease may be at greater risk for adverse effects from venlafaxine due to decreased drug clearance.  Therapy with venlafaxine should be administered cautiously in patients with impaired renal and/or hepatic function.  A reduction in the total daily dosage is recommended.  The manufacturer suggests a 50% reduction in patients with moderate hepatic impairment (possibly more in patients with cirrhosis), a 25% reduction in patients with mild to moderate renal impairment, and a 50% reduction in patients undergoing hemodialysis (to be administered after dialysis treatment).', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30945, 29214, 'Venlafaxine', 'Liver Diseases', 'Venlafaxine is metabolized by the liver, and both the parent drug and metabolites are excreted by the kidney.  Patients with renal and/or liver disease may be at greater risk for adverse effects from venlafaxine due to decreased drug clearance.  Therapy with venlafaxine should be administered cautiously in patients with impaired renal and/or hepatic function.  A reduction in the total daily dosage is recommended.  The manufacturer suggests a 50% reduction in patients with moderate hepatic impairment (possibly more in patients with cirrhosis), a 25% reduction in patients with mild to moderate renal impairment, and a 50% reduction in patients undergoing hemodialysis (to be administered after dialysis treatment).', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30946, 30447, 'Venlafaxine', 'Liver Diseases', 'Venlafaxine is metabolized by the liver, and both the parent drug and metabolites are excreted by the kidney.  Patients with renal and/or liver disease may be at greater risk for adverse effects from venlafaxine due to decreased drug clearance.  Therapy with venlafaxine should be administered cautiously in patients with impaired renal and/or hepatic function.  A reduction in the total daily dosage is recommended.  The manufacturer suggests a 50% reduction in patients with moderate hepatic impairment (possibly more in patients with cirrhosis), a 25% reduction in patients with mild to moderate renal impairment, and a 50% reduction in patients undergoing hemodialysis (to be administered after dialysis treatment).', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30947, 31559, 'Venlafaxine', 'Liver Diseases', 'Venlafaxine is metabolized by the liver, and both the parent drug and metabolites are excreted by the kidney.  Patients with renal and/or liver disease may be at greater risk for adverse effects from venlafaxine due to decreased drug clearance.  Therapy with venlafaxine should be administered cautiously in patients with impaired renal and/or hepatic function.  A reduction in the total daily dosage is recommended.  The manufacturer suggests a 50% reduction in patients with moderate hepatic impairment (possibly more in patients with cirrhosis), a 25% reduction in patients with mild to moderate renal impairment, and a 50% reduction in patients undergoing hemodialysis (to be administered after dialysis treatment).', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30948, 32779, 'Venlafaxine', 'Liver Diseases', 'Venlafaxine is metabolized by the liver, and both the parent drug and metabolites are excreted by the kidney.  Patients with renal and/or liver disease may be at greater risk for adverse effects from venlafaxine due to decreased drug clearance.  Therapy with venlafaxine should be administered cautiously in patients with impaired renal and/or hepatic function.  A reduction in the total daily dosage is recommended.  The manufacturer suggests a 50% reduction in patients with moderate hepatic impairment (possibly more in patients with cirrhosis), a 25% reduction in patients with mild to moderate renal impairment, and a 50% reduction in patients undergoing hemodialysis (to be administered after dialysis treatment).', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30949, 4005, 'Venlafaxine', 'Mania', 'All antidepressants may occasionally cause mania or hypomania, particularly in patients with bipolar disorder.  Therapy with antidepressants should be administered cautiously in patients with a history of mania/hypomania.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30950, 4006, 'Venlafaxine', 'Mania', 'All antidepressants may occasionally cause mania or hypomania, particularly in patients with bipolar disorder.  Therapy with antidepressants should be administered cautiously in patients with a history of mania/hypomania.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30951, 4010, 'Venlafaxine', 'Mania', 'All antidepressants may occasionally cause mania or hypomania, particularly in patients with bipolar disorder.  Therapy with antidepressants should be administered cautiously in patients with a history of mania/hypomania.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30952, 6386, 'Venlafaxine', 'Mania', 'All antidepressants may occasionally cause mania or hypomania, particularly in patients with bipolar disorder.  Therapy with antidepressants should be administered cautiously in patients with a history of mania/hypomania.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30953, 12174, 'Venlafaxine', 'Mania', 'All antidepressants may occasionally cause mania or hypomania, particularly in patients with bipolar disorder.  Therapy with antidepressants should be administered cautiously in patients with a history of mania/hypomania.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30954, 17234, 'Venlafaxine', 'Mania', 'All antidepressants may occasionally cause mania or hypomania, particularly in patients with bipolar disorder.  Therapy with antidepressants should be administered cautiously in patients with a history of mania/hypomania.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30955, 17235, 'Venlafaxine', 'Mania', 'All antidepressants may occasionally cause mania or hypomania, particularly in patients with bipolar disorder.  Therapy with antidepressants should be administered cautiously in patients with a history of mania/hypomania.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30956, 17236, 'Venlafaxine', 'Mania', 'All antidepressants may occasionally cause mania or hypomania, particularly in patients with bipolar disorder.  Therapy with antidepressants should be administered cautiously in patients with a history of mania/hypomania.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30957, 18100, 'Venlafaxine', 'Mania', 'All antidepressants may occasionally cause mania or hypomania, particularly in patients with bipolar disorder.  Therapy with antidepressants should be administered cautiously in patients with a history of mania/hypomania.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30958, 18106, 'Venlafaxine', 'Mania', 'All antidepressants may occasionally cause mania or hypomania, particularly in patients with bipolar disorder.  Therapy with antidepressants should be administered cautiously in patients with a history of mania/hypomania.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30959, 19873, 'Venlafaxine', 'Mania', 'All antidepressants may occasionally cause mania or hypomania, particularly in patients with bipolar disorder.  Therapy with antidepressants should be administered cautiously in patients with a history of mania/hypomania.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30960, 19874, 'Venlafaxine', 'Mania', 'All antidepressants may occasionally cause mania or hypomania, particularly in patients with bipolar disorder.  Therapy with antidepressants should be administered cautiously in patients with a history of mania/hypomania.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30961, 19875, 'Venlafaxine', 'Mania', 'All antidepressants may occasionally cause mania or hypomania, particularly in patients with bipolar disorder.  Therapy with antidepressants should be administered cautiously in patients with a history of mania/hypomania.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30962, 20709, 'Venlafaxine', 'Mania', 'All antidepressants may occasionally cause mania or hypomania, particularly in patients with bipolar disorder.  Therapy with antidepressants should be administered cautiously in patients with a history of mania/hypomania.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30963, 20711, 'Venlafaxine', 'Mania', 'All antidepressants may occasionally cause mania or hypomania, particularly in patients with bipolar disorder.  Therapy with antidepressants should be administered cautiously in patients with a history of mania/hypomania.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30964, 20712, 'Venlafaxine', 'Mania', 'All antidepressants may occasionally cause mania or hypomania, particularly in patients with bipolar disorder.  Therapy with antidepressants should be administered cautiously in patients with a history of mania/hypomania.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30965, 21072, 'Venlafaxine', 'Mania', 'All antidepressants may occasionally cause mania or hypomania, particularly in patients with bipolar disorder.  Therapy with antidepressants should be administered cautiously in patients with a history of mania/hypomania.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30966, 29096, 'Venlafaxine', 'Mania', 'All antidepressants may occasionally cause mania or hypomania, particularly in patients with bipolar disorder.  Therapy with antidepressants should be administered cautiously in patients with a history of mania/hypomania.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30967, 29097, 'Venlafaxine', 'Mania', 'All antidepressants may occasionally cause mania or hypomania, particularly in patients with bipolar disorder.  Therapy with antidepressants should be administered cautiously in patients with a history of mania/hypomania.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30968, 29098, 'Venlafaxine', 'Mania', 'All antidepressants may occasionally cause mania or hypomania, particularly in patients with bipolar disorder.  Therapy with antidepressants should be administered cautiously in patients with a history of mania/hypomania.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30969, 29099, 'Venlafaxine', 'Mania', 'All antidepressants may occasionally cause mania or hypomania, particularly in patients with bipolar disorder.  Therapy with antidepressants should be administered cautiously in patients with a history of mania/hypomania.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30970, 29103, 'Venlafaxine', 'Mania', 'All antidepressants may occasionally cause mania or hypomania, particularly in patients with bipolar disorder.  Therapy with antidepressants should be administered cautiously in patients with a history of mania/hypomania.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30971, 29110, 'Venlafaxine', 'Mania', 'All antidepressants may occasionally cause mania or hypomania, particularly in patients with bipolar disorder.  Therapy with antidepressants should be administered cautiously in patients with a history of mania/hypomania.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30972, 29111, 'Venlafaxine', 'Mania', 'All antidepressants may occasionally cause mania or hypomania, particularly in patients with bipolar disorder.  Therapy with antidepressants should be administered cautiously in patients with a history of mania/hypomania.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30973, 29212, 'Venlafaxine', 'Mania', 'All antidepressants may occasionally cause mania or hypomania, particularly in patients with bipolar disorder.  Therapy with antidepressants should be administered cautiously in patients with a history of mania/hypomania.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30974, 29213, 'Venlafaxine', 'Mania', 'All antidepressants may occasionally cause mania or hypomania, particularly in patients with bipolar disorder.  Therapy with antidepressants should be administered cautiously in patients with a history of mania/hypomania.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30975, 29214, 'Venlafaxine', 'Mania', 'All antidepressants may occasionally cause mania or hypomania, particularly in patients with bipolar disorder.  Therapy with antidepressants should be administered cautiously in patients with a history of mania/hypomania.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30976, 30447, 'Venlafaxine', 'Mania', 'All antidepressants may occasionally cause mania or hypomania, particularly in patients with bipolar disorder.  Therapy with antidepressants should be administered cautiously in patients with a history of mania/hypomania.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30977, 31559, 'Venlafaxine', 'Mania', 'All antidepressants may occasionally cause mania or hypomania, particularly in patients with bipolar disorder.  Therapy with antidepressants should be administered cautiously in patients with a history of mania/hypomania.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30978, 32779, 'Venlafaxine', 'Mania', 'All antidepressants may occasionally cause mania or hypomania, particularly in patients with bipolar disorder.  Therapy with antidepressants should be administered cautiously in patients with a history of mania/hypomania.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30979, 4005, 'Venlafaxine', 'Glaucoma', 'SNRI antidepressants cause pupillary dilation that may trigger an angle closure attack in patients with anatomically narrow angle without iridectomy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30980, 4006, 'Venlafaxine', 'Glaucoma', 'SNRI antidepressants cause pupillary dilation that may trigger an angle closure attack in patients with anatomically narrow angle without iridectomy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30981, 4010, 'Venlafaxine', 'Glaucoma', 'SNRI antidepressants cause pupillary dilation that may trigger an angle closure attack in patients with anatomically narrow angle without iridectomy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30982, 6386, 'Venlafaxine', 'Glaucoma', 'SNRI antidepressants cause pupillary dilation that may trigger an angle closure attack in patients with anatomically narrow angle without iridectomy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30983, 12174, 'Venlafaxine', 'Glaucoma', 'SNRI antidepressants cause pupillary dilation that may trigger an angle closure attack in patients with anatomically narrow angle without iridectomy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30984, 17234, 'Venlafaxine', 'Glaucoma', 'SNRI antidepressants cause pupillary dilation that may trigger an angle closure attack in patients with anatomically narrow angle without iridectomy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30985, 17235, 'Venlafaxine', 'Glaucoma', 'SNRI antidepressants cause pupillary dilation that may trigger an angle closure attack in patients with anatomically narrow angle without iridectomy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30986, 17236, 'Venlafaxine', 'Glaucoma', 'SNRI antidepressants cause pupillary dilation that may trigger an angle closure attack in patients with anatomically narrow angle without iridectomy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30987, 18100, 'Venlafaxine', 'Glaucoma', 'SNRI antidepressants cause pupillary dilation that may trigger an angle closure attack in patients with anatomically narrow angle without iridectomy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30988, 18106, 'Venlafaxine', 'Glaucoma', 'SNRI antidepressants cause pupillary dilation that may trigger an angle closure attack in patients with anatomically narrow angle without iridectomy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30989, 19873, 'Venlafaxine', 'Glaucoma', 'SNRI antidepressants cause pupillary dilation that may trigger an angle closure attack in patients with anatomically narrow angle without iridectomy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30990, 19874, 'Venlafaxine', 'Glaucoma', 'SNRI antidepressants cause pupillary dilation that may trigger an angle closure attack in patients with anatomically narrow angle without iridectomy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30991, 19875, 'Venlafaxine', 'Glaucoma', 'SNRI antidepressants cause pupillary dilation that may trigger an angle closure attack in patients with anatomically narrow angle without iridectomy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30992, 20709, 'Venlafaxine', 'Glaucoma', 'SNRI antidepressants cause pupillary dilation that may trigger an angle closure attack in patients with anatomically narrow angle without iridectomy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30993, 20711, 'Venlafaxine', 'Glaucoma', 'SNRI antidepressants cause pupillary dilation that may trigger an angle closure attack in patients with anatomically narrow angle without iridectomy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30994, 20712, 'Venlafaxine', 'Glaucoma', 'SNRI antidepressants cause pupillary dilation that may trigger an angle closure attack in patients with anatomically narrow angle without iridectomy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30995, 21072, 'Venlafaxine', 'Glaucoma', 'SNRI antidepressants cause pupillary dilation that may trigger an angle closure attack in patients with anatomically narrow angle without iridectomy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30996, 29096, 'Venlafaxine', 'Glaucoma', 'SNRI antidepressants cause pupillary dilation that may trigger an angle closure attack in patients with anatomically narrow angle without iridectomy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30997, 29097, 'Venlafaxine', 'Glaucoma', 'SNRI antidepressants cause pupillary dilation that may trigger an angle closure attack in patients with anatomically narrow angle without iridectomy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30998, 29098, 'Venlafaxine', 'Glaucoma', 'SNRI antidepressants cause pupillary dilation that may trigger an angle closure attack in patients with anatomically narrow angle without iridectomy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30999, 29099, 'Venlafaxine', 'Glaucoma', 'SNRI antidepressants cause pupillary dilation that may trigger an angle closure attack in patients with anatomically narrow angle without iridectomy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31000, 29103, 'Venlafaxine', 'Glaucoma', 'SNRI antidepressants cause pupillary dilation that may trigger an angle closure attack in patients with anatomically narrow angle without iridectomy.', '2', '', 'DDInter', 0);
